Evonile Pharma Q2 FY27 Results: Standalone Net Loss ₹77.54 Crore on Total Income of ₹63.79 Crore
- Earnings
- Pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Evonile Pharma (NSE: NOVARTIND) reported a standalone net loss of ₹77.54 crore and total income of ₹63.79 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. The quarter's loss before tax was ₹101.06 crore after exceptional items of ₹682.6 million.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹63.79 crore, down 36.0% YoY and 43.3% QoQ
- Net profit: Loss of ₹77.54 crore against a profit of ₹24.22 crore a year earlier
- EPS and tax: Basic EPS of -₹31.41; tax credit of ₹23.52 crore
- Exceptional items: ₹682.6 million charge, including ₹610.0 million on termination of related arrangements with a major customer
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 63.79 | 99.73 | -36.0% | 112.55 | -43.3% | |
| Revenue from operations | 56.05 | 90.33 | -37.9% | 103.81 | -46.0% |
| Other income | 7.74 | 9.40 | -17.7% | 8.74 | -11.4% |
| -77.54 | 24.22 | n/a | 32.21 | n/a | |
| Profit before tax | -101.06 | 32.65 | n/a | 43.17 | n/a |
| Finance costs | 4.83 | 0.11 | n/a | 0.06 | n/a |
| Depreciation | 3.89 | 0.52 | +648.1% | 0.42 | +826.2% |
| Tax expense | -23.52 | 8.43 | n/a | 10.96 | n/a |
| Net profit margin | -121.56% | 24.29% | -145.84 pp | 28.62% | -150.17 pp |
| EPS, basic (₹) | -31.41 | 9.81 | n/a | 13.05 | n/a |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The quarter moved from profit to a large loss, and the fall is in operating income. Revenue from operations fell 37.9% YoY to ₹56.05 crore, more than other income, which fell 17.7% to ₹7.74 crore. Other income made up 12.1% of total income this quarter.
Costs rose sharply below the operating line. Depreciation went from ₹0.52 crore to ₹3.89 crore and finance costs from ₹0.11 crore to ₹4.83 crore, with finance costs equal to 7.6% of total income. The notes list exceptional items of ₹682.6 million, comprising ₹610.0 million from termination of related arrangements with a major customer and ₹72.6 million from impairment of an import licence carrying value. Other expenses include one-time transition and acquisition expenses of ₹154.2 million.
The tax line is a credit of ₹23.52 crore against a charge of ₹8.43 crore a year earlier. The company says it recognised deferred tax assets based on management's business projections and assessment of future taxable profits. The company has also capitalised ₹12,900.0 million of intangible assets from an asset purchase agreement with Pfizer dated 7 Sep 2026, including stamp duty of ₹400.0 million.
Inference
The company's name changed from Novartis India Limited to Evonile Pharma Limited after shareholder approval on 24 Sep 2026.
The Board approved on 8 Oct 2026 a rights issue of partly paid-up equity shares of up to ₹9,000.0 million, subject to regulatory approval.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
